1. Pink Sheet
  2. >>Market Access

340B Reform Remains Elusive Even As Spending Increases

 
• By Michael Cipriano

Total purchases at 340B prices by 2021 are projected to exceed $23 bil – more than total Medicare Part B drug reimbursement in 2014.

RollOfDollarswithPills_1200x675

Industry, advocates and legislators are in agreement that there must be changes to the federal 340B Drug Discount Program to control its growth, but it remains unclear which direction Congress will go to solve the issue.

Ted Alexander, a senior legislative assistant for House Energy & Commerce Health Subcommittee member Rep. Chris Collins (R-N.Y.), acknowledged that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Woodcock: Do Not Do The Wrong Study, Even If Against US FDA Advice

 
• By Sarah Karlin-Smith

The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.

UK Looks To Auto-Match NHS Patients With Clinical Trials To Boost Recruitment

 
• By Vibha Sharma

The UK government is making it easier for millions of people to participate in clinical trials and is boosting transparency around how studies are delivered across the National Health Service.